Health ingredient provider Solabia Nutrition has received an approval letter from the US Food and Drug Administration (FDA) for their two branded flagship ingredients, WATTS'UP and Cordiart.
This FDA notice means that the sweet orange-derived citrus sinensis extracts are now available to US functional food and dietary supplement manufacturers for use in a variety of dosage forms.
WATTS'UP is a clinically validated nutraceutical that has been shown to support power output and sports performance in athletes and active individuals.
A recent consumer study conducted on the product found that taking 400mg of WATTS'UP daily could also benefit sports recovery as well.
Meanwhile, Cordiart is a vascular health ingredient that is touted for its capacity to enhance blood flow, while improving flow-mediated dilation.
At a dose of 500mg, the nutraceutical has been adopted into various finished product formats, including capsules, powder blends and softgels.
Both ingredients are of natural origin and clean label, while being suitable for a range of formula types, including liquids, powders, beverages and sachets.
By achieving GRAS designation, Solabia has demonstrated the safety of these products for consumption with scientific evidence.
“Receiving the FDA’s Approval letter for GRAS status is a major milestone that underscores our commitment to safety, science, and innovation,” said Alessandra Rinaldi, Quality & Regulatory Manager at Solabia Nutrition.
“This recognition further enables our customers to confidently formulate with WATTS’UP and Cordiart across a wide range of delivery systems and product categories.”
